Table 1.
Soluble factors, mediators, circulating chemokines, remodeling enzymes | Action in burns | Action in fistula formation | Action in fibrosis | Temperature effects | Effect of cooling on activity or expression |
---|---|---|---|---|---|
TNF- α | Proinflammatory cytokine | Triggers EMT, onset and progression of fistula formation | Induces apoptosis of fibrotic progenitors | Cooling significantly reduces activity | |
TGF-β | Worsens scar formation | Triggers EMT, onset and progression of fistula formation | Induces fibrosis | Cooling reduces mRNA expression | |
Angiotensin II | Possible synergistic signal to TGF-β in burn scarring | Unclear actions | Expression of genes related to fibrosis | Lowers body temperature when administered systemically | |
IL-1 | Proinflammatory cytokine (inhibited by IL-1ra) | Inhibition alleviates severe fistulae in hidradenitis suppurativa | Profibrotic cytokine induces apoptosis of fibrotic progenitors | Downregulated or unchanged with cooling | |
IL-4 | Anti-inflammatory cytokine | Implicated in oronasal fistula formation | Facilitates muscle regeneration | Expression levels of IL-4 anti-inflammatory cytokines increased | |
IL-6 | Proinflammatory cytokine associated with mortality | Induced by TNF-α, increases permeability of the endothelial layer | Triggers cardiac fibrogenic signaling cascade | Reduces IL-6 expression | |
IL-7 | Proinflammatory cytokine | Unclear actions | May inhibit high glucose-induced renal proximal tubular fibrosis | Uncertain | |
IL-8 | Enhances neutrophil transmigration; proinflammatory cytokine associated with ARDS | Putative role in the pathogenesis of cryptoglandular anal fistula | Dominates the inflammatory profile in cystic fibrosis | Higher levels may determine severity hypoxic ischemia | |
IL-10 | Anti-inflammatory cytokine, associated with burn mortality | Impaired IL-10 signaling implicated in inflammatory bowel fistulas | Profibrotic cytokine | Elevations delayed with hypothermia | |
IL-12 | Proinflammatory cytokine stimulates the production of TNF-α | Elevated levels linked to enterocutaneous fistulas | Induces apoptosis of fibrotic progenitors | Reduced expression with hypothermia | |
IL-13 | Anti-inflammatory cytokine induces metaplasia | Triggers EMT, onset and progression of fistula formation | Effects muscle regeneration by resident mesenchymal progenitor cells | Expression levels increased with hypothermia | |
IL-17 | Proinflammatory cytokine increased during burn injuries | Proinflammatory mediator; key role in fistula formation in hidradenitis suppurativa | Mediator in foreign body response and fibrosis | Gene expression levels significantly downregulated with local cryotherapy | |
Matrix metalloproteinases (MMPs): MMP-1, MMP-3, MMP-9 | Upregulated in vascular inflammation | Activated by EMT, causing further tissue damage and inflammation | Associated with fibrotic processes underlying right ventricular remodeling | Downregulatory effects on expression | |
Histamine | Increases wound edema, microvascular permeability | Unclear actions | Unclear actions | Decreases or prevents histamine release | |
Reactive oxygen species | Induce burn progression, edema formation, and microvascular permeability | Implicated in enterocutaneous fistula development | Associated with severity of cystic fibrosis | Reduced with hypothermia |
Both fibrosis and epithelial-to-mesenchymal transition (EMT) are drivers of fistula development after an initial thermal injury, and the soluble mediators of these processes are also implicated in burn wound conversion, which further facilitates the progression of thermal injury. The activity of many proinflammatory markers is inhibited by cooling.
ARDS = acute respiratory distress syndrome; IL-1 through IL-17 = interleukin 1 through 17; MMP = matrix metalloproteinase; TGF-β = tumor growth factor beta; TNF-α = tumor necrosis factor alpha.